Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 221, Issue 1-2, Pages 101-106Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2010.02.013
Keywords
Myasthenia gravis; CXCL13; Chemokine; Gene expression microarray
Categories
Funding
- National Health Research Institutes
Ask authors/readers for more resources
Myasthenia gravis (MG) is an antibody and complement mediated autoimmune disease. Serum CXC chemokine ligand 13 (CXCL13) was found to be elevated in MG patients and high CXCL13 level was associated with severe clinical stages, especially in females with thymic lymphoid hyperplasia. Both protein and mRNA of CXCL13 and CXC chemokine receptor 5 (CXCR5) in the thymic tissues were significantly higher in MG patients with lymphoid hyperplasia than those with thymoma. Our data indicated that serum CXCL13 can be used as an index of disease severity and ectopic thymic expression of CXCL13 might be associated with aberrant cell trafficking to the thymus of MG. (C) 2010 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available